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Background: Drug-resistant tuberculosis (DR-TB) remains a threat to global public health, owing to the complexity
and delay of diagnosis and treatment. The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD)
was formed to develop and evaluate assays designed to rapidly detect DR-TB, so that appropriate treatment might
begin more quickly. This paper describes the methodology employed in a prospective cohort study for head-to-head
assessment of three different rapid diagnostic tools.
Methods: Subjects at risk of DR-TB were enrolled from three countries. Data were gathered from a combination of
patient interviews, chart reviews, and laboratory testing from each site’s reference laboratory. The primary outcome
of interest was reduction in time from specimen arrival in the laboratory to results of rapid drug susceptibility tests,
as compared with current standard mycobacterial growth indicator tube (MGIT) drug susceptibility tests.
Results: Successful implementation of the trial in diverse multinational populations is explained, in addition to
challenges encountered and recommendations for future studies with similar aims or populations.
Conclusions: The GCDD study was a head-to-head study of multiple rapid diagnostic assays aimed at improving
accuracy and precision of diagnostics and reducing overall time to detection of DR-TB. By conducting a large
prospective study, which captured epidemiological, clinical, and biological data, we have produced a high-quality
unique dataset, which will be beneficial for analyzing study aims as well as answering future DR-TB research questions.
Reduction in detection time for XDR-TB would be a major public health success as it would allow for improved treatment
and more successful patient outcomes. Executing successful trials is critical in assessment of these reductions in highly
variable populations.
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Tuberculosis (TB) is among the top threats to global
public health, ranked second only to HIV as the most
deadly infectious disease worldwide by the World Health
Organization (WHO) [1]. Achievements in TB control
over the last decade have led to a slow decline in TB
incidence of 2% per year [1]; however, drug-resistant TB
(DR-TB) remains a serious public health concern
globally. The WHO estimated that in 2012 there were
450,000 new multidrug-resistant TB (MDR-TB) cases;
that is, cases of TB resistant to first-line drugs isoniazid
and rifampin. Additionally, an estimated 9.6% of MDR-
TB cases were also extensively drug-resistant (XDR-TB),
having additional resistance to fluoroquinolones, such as
ofloxacin and moxifloxacin, and at least one of the
injectable anti-TB drugs (capreomycin, kanamycin, and
amikacin), making treatment virtually impossible in
countries without access to alternative drugs.
Critically, the WHO reported that fewer than 25% of
the 450,000 estimated MDR-TB cases in 2012 were actually
detected [1]. Drug-resistant TB can be managed success-
fully only if it is diagnosed rapidly using drug susceptibility
testing, allowing for prompt and appropriate treatment.
Standard, culture-based phenotypic drug susceptibility
tests take weeks to months for results, which delays treat-
ment and can significantly impact TB treatment outcomes
[2]. Delayed patient management decisions contribute to
amplification of resistance, transmission of DR-TB to unin-
fected individuals, and higher mortality rates. Studies have
shown that if TB is correctly diagnosed and promptly
treated, transmission to uninfected individuals is quickly
reduced; however, if diagnosis and treatment are delayed
or if TB is not detected, spread of DR-TB is likely [3,4].
In 2008, the United States National Institutes of Health
placed the development and testing of technologies for
rapid drug resistance detection at the top of their list of TB
research priorities [5]. The Global Consortium for Drug-
resistant Tuberculosis Diagnostics (GCDD) was established
in 2008 to characterize the genetic basis of drug resistance
and evaluate molecular and microbiological methods of
detecting DR-TB quickly and efficiently. This international
collaboration to improve current DR-TB diagnostics gath-
ered data from three unique regions in an effort to improve
accuracy and precision of novel diagnostics and reduce
DR-TB detection time. Here we explain the methods
employed by GCDD investigators to conduct a multi-
national longitudinal cohort study that addresses these
objectives.
Aims and hypotheses
Study aims were defined as follows in the approved
protocol of the National Institute of Allergy and Infectious
Diseases Division of Microbiology and Infectious Diseases
(text edited for clarity and brevity):Aim 1: To reduce the average XDR-TB detection time
from months to a week. We will compare the performance
of one existing line probe assay (Hain GenoType®MTBDR-
plus and Hain GenoType®MTBDRsl) with a newly de-
veloped sequence-based assay (pyrosequencing) and an
expanded Microscopic Observation Drug Susceptibility
(MODS) phenotypic assay, to detect resistance to isoniazid
and rifampin, ofloxacin, moxifloxacin, kanamycin, amika-
cin, and capreomycin.
Aim 2: To determine agreement between rapid tests
and standard drug susceptibility test results. Results of
rapid tests based on smear-positive sputum will be com-
pared with those from the current gold-standard drug
susceptibility test method, which is based on subculture
of Mycobacterium tuberculosis growth in the MGIT 960
liquid culture system.
Aim 3: To identify the genetic basis of discordant
results from Aim 2. Strains identified as drug resistant
by the drug susceptibility test, but not by the gene-based
molecular tests, will be further examined through
sequencing target genes, neighboring genes, or the entire
genomes of unique strain families.
Aim 4: To characterize XDR-TB strains globally.
Genotypic, phenotypic, and epidemiological features, as
well as geographical relationships of XDR-TB strains,
will be characterized and compared with other drug-
resistant and susceptible strains. We will explore the re-
lationships between drug resistance, including XDR-TB,
and patient risk factors and strain families of M.
tuberculosis.
Secondary aims
Secondary Aim 1: Cost-effectiveness study. The costs
associated with performing each rapid test will be
compared with improvements in time and accuracy for
detecting drug resistance and XDR-TB over standard
drug susceptibility testing methods.
Secondary Aim 2: To determine the predictive value of
resistance-associated mutations in determining sputum
culture conversion.
Methods
The GCDD study design was conducted in two phases.
Phase I involved the creation of a specimen repository
by requesting banked isolates of M. tuberculosis from
TB centers in four geographically distinct sites that in-
cluded Manila, the Philippines; Mumbai, India; Chisinau,
Moldova; and Port Elizabeth, South Africa. The isolates
requested were selected to maximize phenotypic and
genotypic diversity in the repository, which would be
used to inform the design and evaluate the performance
of molecular assays for detecting drug-resistant TB.
Upon receipt, all repository isolates were genotyped
using 12 mycobacterial interspersed repetitive units,
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ity tests were also performed using MGIT 960 according
to the manufacturer’s instructions. Additional methods
and results of this study have been described elsewhere
[6]. Data from this repository were used to inform the
design of diagnostic tests that were evaluated in the
second phase.
Phase II, which is the focus of this paper, consisted of
a prospective cohort study designed to evaluate a number
of rapid drug susceptibility tests compared with the stand-
ard MGIT 960 assay among patients with suspected, but
not confirmed, XDR-TB in existing clinical laboratories in
three of the countries included in Phase I. Participants
were screened for eligibility and provided written informed
consent prior to enrollment. Biological specimens and
patient interview data were collected at baseline and 52-
week follow-up visits. In addition, medical record reviews
were conducted at baseline, 30 days post-enrollment and
52 weeks post-enrollment. Sputum specimens collected
were tested using MGIT drug susceptibility tests, line
probe assay, pyrosequencing, and MODS assay. In addition
to the results of a rigorously standardized, direct compari-
son of the performance of these assays, this study produced
a well-characterized repository of M. tuberculosis isolates
to address many other clinical, laboratory and epidemio-
logic questions. This paper describes the methodology used
for the prospective cohort study.
Study sites
Participants were enrolled from three diverse regions with
a high prevalence of XDR-TB: Mumbai, India; Chisinau,
Moldova; and Port Elizabeth, South Africa. These sites
were carefully considered when planning the study and
were selected because of a high documented risk of DR-TB
and the ethnic diversity of these regions.
India
The PD Hinduja National Hospital and Medical Research
Centre is a tertiary care center in central Mumbai, India
that provides medical care in all specialties of Medicine and
Surgery. The Pulmonary Department at the PD Hinduja
National Hospital is the busiest in Mumbai and is the refer-
ral center for MDR and XDR-TB cases of the city and the
state of Maharashtra. Therefore, the TB patient population
is more likely to contain those who have previously been
treated and were either unresponsive or relapsed [7]. In a
consecutive sampling of 150 patients in the Mumbai area,
80% of samples obtained were found to be resistant to one
or more standard TB medications, while 51% were resistant
to more than one drug [7].
Moldova
The Phthisiopneumology Institute in Chisinau, Moldova,
the central unit of the Moldovan National TB ControlProgramme, is a scientific research, medical consult-
ation, and training center, which leads all TB and unspe-
cific upper respiratory tract diseases services for patients
across Moldova. Disintegration of the Soviet Union in
the early 1990s resulted in a sudden and sharp deterior-
ation of socioeconomic conditions in Moldova, leading
to an upsurge in TB from increased infection and
increased risk of breakdown from infection to disease. A
financial crisis led to drug shortages and inadequate and
interrupted treatment. As a result, drug resistance
increased with the eventual emergence and transmission
of MDR strains. The prevalence of MDR-TB in Moldova
has been documented as 24% of new and 62% of previ-
ously treated patients, according to national TB surveil-
lance data between 2007 and 2010 [8].South Africa
South Africa is one of the five countries with the largest
number of incident TB cases in 2011, estimated to be
between 0.4 million and 0.6 million, according to the
WHO. Co-infection with HIV is of particular concern in
this region, with 65% of patients with TB known to be
HIV-positive [9]. In Port Elizabeth, patients were enrolled
at six Primary Health Care facilities and one regional
hospital. Decentralized enrollment resulted in a different
prevalence of drug resistance at this site.Eligibility
Newly presenting patients with TB who were 5 years of
age and older, and patients for whom treatment failed,
were recruited from each of the study clinics. Owing to
varying circumstances and constraints affecting recruit-
ment at each site, local recruitment procedures were docu-
mented in site-specific standard operating procedures and
sent to the study coordinators prior to enrollment. For
example, the frequency of recruitment was expected to
vary among the study sites to accommodate differences in
clinical staffing of the study, enrollment locations, and
laboratory capacity. All site-specific standard operating
procedures followed the same general guidelines set forth
in the GCDD study clinical protocol. Study protocols were
approved by the institutional review board of the Univer-
sity of California, San Diego (Project No. 1100383) and by
the institutional review board of each enrolling site: PD
Hinduja National Hospital and Medical Research Centre,
Project Number. 507-09-CR; the Ministry of Health
Care of the Republic of Moldova, Institution of Public
Health, and Ethics Committee of the Phthisiopneumology
Institute of Moldova (no applicable reference number); and
Universiteit-Stellenbosch University Health Research Ethics
Committee Tygerberg, South Africa, ethics reference num-
ber N10/08/261.
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Participants were included in the study if they
– Were at least 5 years of age
– Were acid-fast bacilli sputum smear-positive , 1+ or
greater (within previous 14 days), positive on
GeneXpert, or present clinically with high suspicion
of active TB and:
– Previously received >1 month of treatment for a
prior TB episode or
– Were failing TB treatment with positive sputum
smear or culture after ≥3 months of a standard
TB treatment or
– Had close contact with a known drug-resistant
TB case or
– Were newly diagnosed with MDR-TB within the
last 30 days or
– Were previously diagnosed with MDR-TB and
failed TB treatment with positive sputum smear or
culture after ≥3 months of a standard MDR-TB
treatment regimen
– Provided informed consent or subject or legal
guardian or representative able and willing to
provide informed consent
Participants were excluded from the study if they
– Were institutionalized
– Were unable to provide at least 7.5 ml sputum
(1st and 2nd samples combined)
– Had results from Second-line drug susceptibility
test performed within the last 3 months
The eligibility criteria for this study were designed to
identify patients at increased risk of DR-TB. Potential
study subjects gave oral consent to be screened for study
eligibility. The screening was performed by a trained
clinical staff member using a computerized algorithm
during a single study visit. Written consent, or assent if
the patient was younger than 18 years old, was collected
if eligibility was confirmed. Children between the ages of
5 and 17 were eligible for the study at sites where the
participation of minors was approved by the local insti-
tutional review board or independent ethics committee.
Subjects were not compensated for participation; how-
ever, in India and South Africa where patients traveled
an hour or more from their residence for study visits not
related to routine care, travel costs were reimbursed.
Participant withdrawal
Enrolled subjects were withdrawn from the study if they
could not provide adequate sputum for testing. Partici-
pants could also request to be withdrawn from the study.
If this occurred, the reasons were documented. Onceparticipants were withdrawn, their study data were
excluded from all analyses. Failure to return for follow-up
or learning of a participant’s death were not considered
reasons for withdrawal from this study.
Training
Prior to study initiation, all personnel gathered in San
Diego, California, USA for training in good clinical prac-
tices and the GCDD protocol. The training in good clinical
practices was conducted by Family Health International,
contracted by the National Institutes of Health and the
National Institute of Allergy and Infectious Diseases, so
that scientists were certified in ethical considerations with
human subjects and international clinical trial protocols.
All domestic and international collaborators also com-
pleted certification in the Collaborative Institutional
Training Initiative.
Clinical and laboratory personnel from each site were
also trained in the use of case report forms and study
laptops, used for clinical data collection. Laboratory
technicians specializing in the pyrosequencing assay
were given detailed training at the California Department
of Public Health in Richmond, California, while those re-
ceiving detailed training in the MODS assay were trained
in Lima, Peru. Site personnel were generally more experi-
enced in the use of line probe assays, so study procedures
were reviewed at the meeting in San Diego. As procedures
for the study were refined or new elements added, follow-
up training was conducted via webinar. These were run by
the staff most knowledgeable in the procedures and were
targeted to certain collaborators at each site. For example,
updates to the clinical case report forms were presented
by the data manager to the enrolling clinicians. Principal
investigators were invited to attend but were not required.
Enrollment procedures
Study procedures were complex and several clinical and
laboratory processes needed to be standardized across
the distinctive sites. Therefore, we included a series of
validation procedures, which utilized enrolled subjects’
samples to validate all data systems and to allow laborator-
ies time to become proficient in all assays and procedures.
Completion of validation procedures was a requirement
to initiate the study.
Following screening and informed consent procedures,
eligible patients were asked to provide a spot sputum
specimen and complete a baseline interview. Patients
were asked to return to the clinic the following day with
a sputum specimen produced upon waking in addition
to a second spot sputum at the clinic. At 52 weeks after
enrollment, subjects were asked to return one final time
to provide a single spot sputum specimen and complete
a brief clinical examination. With the subject’s consent,
medical record reviews were conducted at baseline, day
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to that obtained during patient interviews and to docu-
ment detailed treatment history for the TB illness
diagnosed at the time of study enrollment. Sputum speci-
mens collected at each visit were sent to the central site
laboratories to be processed for testing. Upon completion,
culture isolates were shipped to the University of California,
San Diego, for storage.
Case report forms
Sources for the data collected for the study included pa-
tient interviews, chart reviews, and laboratory processing
information. Standardized case report forms developed
by researchers at the University of California, San Diego,
gathered all clinical and laboratory processing informa-
tion. Table 1 lists all study case report forms and samples,
and the times at which each were collected.
Interviews
The baseline interview gathered demographic measures
such as age, race, ethnicity, and sex. Known TB risk factors
were assessed at baseline and for the previous three
months. Maps were given to each enrolling clinician so
that detailed geographical history could be assessed; this
was used for spatial analyses. A clinical history wasTable 1 Data collection schedule
Tests, measures, and samples Clinic or
Sputum sample Cl
Blood sample (some study sites) Cl
Screening interview Cl
Enrollment interview Cl
Enrollment chart review Cl
Day-2 specimen collection Cl
30-day chart review Cl
52-week interview Cl








Mycobacterial growth indicator tube drug susceptibility test Labo
Hain GenoType®MTBDRplus Labo
Hain GenoType®MTBDRsl Labo
Microscopic observation drug susceptibility assay Labo
Pyrosequencing Labo
Freezing and storage Laboobtained at this visit, including current symptoms, co-
occurring conditions, HIV or AIDS status, height, and
weight. The follow-up interview was less detailed and
assessed subject’s treatment status, current symptoms,
height, and weight.
Chart reviews
The baseline chart review included measures of the
subject’s current TB category (new or previously treated),
TB drug history beginning from diagnosis of the current
illness, history of chest X-ray and results, and HIV status. If
HIV-positive, CD4 counts and viral loads were requested.
The 30-day chart review documented the subject’s current
status, TB drug history beginning from diagnosis of the
current illness and, if unavailable at baseline, HIV status.
The 52-week chart review assessed the subject’s current
status, TB drug history beginning from diagnosis of the
current illness, history of smear and culture performed
since study entry, and results of the most recent chest
X-ray, if performed.
Laboratory data collection
Using the standard laboratory case report form, labora-
tories recorded the date and time of the collection and
receipt of the sputum samples. Information on thelaboratory Baseline Day 2 30 days 52 weeks
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Sputum processing was performed using the standard
N-acetyl-L-cysteine sodium hydroxide method [10]. The
date and time that cultures were started and completed
were recorded, and later used to calculate the culture
time to detection. Culture and MGIT drug susceptibility
test results were transcribed from the MGIT 960 instru-
ment, while standardized worksheets were used to
record observed data from the MODS assay. Line probe
assay results were recorded directly onto laboratory case
report forms. The line probe assay strips were scanned
for later verification. Pyrosequencing data were tran-
scribed onto the laboratory case report form from the
Pyromark Q96 instrument after comparison with the
Pyrosequencing Library [11]. Pyrograms were saved as.
pdf and uploaded to the website for further analysis.
Owing to standard batching procedures, results for
several patients could appear in test results. This transfer
of information allowed data for a subject coming from
several sources to be gathered in one location.
Reference standard and rapid tests
The reference standard for phenotypic observation of
drug susceptibility test used in this study was the MGIT
960 TB system. The study drugs described in Aim 1,
as well as isoniazid and rifampin, were tested using a
MGIT drug susceptibility test when the culture tested
positive, while sputa from each subject were tested with
the three rapid tests regardless of culture status. Proce-
dures were as follows.
Mycobacterial growth indicator tube drug susceptibility test
In MGIT drug susceptibility testing, the drug suscepti-
bility of TB is based on the modified proportion method
(Food and Drug Administration approved for first-line
anti-TB drugs). The critical proportion for resistance is
taken as 1% for all anti-TB drugs, meaning that if 1% or
more of the test mycobacterial population is resistant,
the culture is considered resistant. We determined re-
sistance by comparing growth in MGIT tubes with and
without drugs; this was accomplished in an instrument
with the capacity to monitor growth of 960 MGIT cul-
ture tubes simultaneously. Although the first-line drugs
were available from Becton Dickinson, the second-line
drugs were not. Thus, testing of second-line drugs was
performed using validated critical concentrations of in-
house (locally prepared by each site) drug solutions
compatible with the WHO recommendations: 2.0 μg/ml
for ofloxacin, 0.25 μg/ml for moxifloxacin, 1.0 μg/ml for
amikacin, and 2.0 μg/ml for capreomycin [12]. As there
were no published WHO recommended critical concen-
trations for kanamycin drug susceptibility testing by
MGIT 960 at the time of the study, we used 2.5 μg/ml,
based concentrations reported in the literature [13,14].Line probe assays
Commercial line probe assays, such as the GenoTy-
pe®MTBDRplus (Hain Lifesciences, Nehren, Germany),
have been well validated for the detection of isoniazid
and rifampin resistance indirectly using TB culture iso-
lates and directly on smear-positive clinical specimens.
Barnard et al. conducted a large study using GenoTy-
pe®MTBDRplus on smear-positive sputum specimens
from 536 patients at a high risk of MDR-TB [15]. They
found a sensitivity and specificity of 98.9% and 99.4%,
respectively, for detection of rifampin resistance; sensi-
tivity was 94.2% with specificity of 99.7% for detection of
isoniazid resistance. Results were interpretable for 97%
of the specimens within 1 or 2 days. Overall, these stud-
ies demonstrate that the strip assay is rapid and accurate
for the detection of mutations found in MDR-TB strains,
providing an excellent platform for development to de-
tect XDR-TB strains. The GenoType®MTBDRsl strip is
marketed as an indirect test but is often used to test
specimens directly for resistance to second-line drugs.
Few studies have been published that evaluate the
performance of the GenoType®MTBDRsl test to detect
resistance to second-line drugs in M. tuberculosis
isolates and sputum specimens. Brossier et al. reported
sensitivities and specificities of the MTBDRsl test in a
study of 49 clinical isolates (41 MDR-TB and 8 XDR-TB)
as follows: fluoroquinolones 87%, 96%; amikacin 100%,
100%; kanamycin 77%, 100%; and capreomycin 80%, 98%
[16]. Kiet et al., in a study of 41 fluoroquinolone resist-
ance isolates and 21 MDR-TB but fluoroquinolone-
sensitive isolates, reported sensitivities and specificities
of the MTBDRsl test as follows: fluoroquinolones 75.6%,
100%; kanamycin 100%, 100% [17]. These studies dem-
onstrate that, because of mutations not included in the
test (such as gyrB), or unknown resistance mechanisms,
the GenoType®MTBDRsl tests lacks the sensitivity to
exclude the possibility of second-line drug resistance
reliably. Both GenoType®MTBDRplus and GenoTy-
pe®MTBDRsl were evaluated in the clinical observation
testing phase.
These assays are based on the principle of amplification
of DNA isolated directly from decontaminated patient
specimens followed by hybridization with specific mem
brane-bound probes using a primer-nucleotide mix. The
first step of the procedure was isolation of mycobacterial
DNA from a decontaminated patient specimen by a heat
and sonication method. The second step involved a multi-
plex amplification with biotinylated primers in a thermal
cycler. A third step involved chemical denaturation of the
amplification products and hybridization of the single-
stranded, biotin-labeled amplicons to membrane-bound
probes. Finally, a streptavidin-alkaline phosphatase conju-
gate was added to initiate an alkaline phosphatase staining
reaction. Each of the reference laboratories had a thermal
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results were interpreted using the template provided with
the kit.
Pyrosequencing
Pyrosequencing is a sequence-based molecular method
to detect mutations associated with drug resistance. The
method requires DNA extraction, amplification by PCR,
and real-time sequencing, using pyrosequencing technol-
ogy and the PyroMarkQ96 platform, as described previ-
ously [11,18]. The GCDD methods for pyrosequencing
were guided by a study conducted by Bravo et al., in which
102 clinical M. tuberculosis isolates were evaluated for
susceptibility to rifampin, isoniazid, and ofloxacin with a
pyrosequencing assay. The sensitivities and specificities of
the assay were 96.7% and 97.3%; 63.8% and 100%; and
70.0% and 100% for the detection of resistance to rifampin,
isoniazid, and ofloxacin, respectively [19]. In this study, we
included eight molecular targets: IS6110, for identification
of M. tuberculosis, katG, the inhA promoter, and ahpC for
isoniazid, rpoB for rifampin, gyrA for quinolones, and rrs
for injectable drugs.
Pyrosequencing was used to rapidly characterize muta-
tions within specific genes associated with resistance to
isoniazid, rifampin, the fluoroquinolones, and the inject-
able drugs. Pyrosequencing was performed according
to the manufacturer’s instructions using the sequence
analysis mode of the Pyromark 96 ID system (Qiagen,
Valencia, CA, USA) and the standard Pyromark Gold
Q96 reagent kit, containing enzyme, substrate, and
nucleotides (Qiagen, Valencia, CA, USA). Briefly, bio
tin-labeled PCR products were immobilized on strep
tavidin-coated sepharose beads and denatured to serve as
single-stranded DNA templates. These beads were subse-
quently transferred to a 96-well plate containing annealing
solution and sequencing primer. The reaction cascade pri-
marily consists of the incorporation of nucleotides into
the growing DNA chain, culminating in the production of
light. The pattern of emitted light in relation to the
nucleotide dispensation order and number of nucleotides
incorporated was subsequently illustrated on a pyrogram.
The data were analyzed using IdentiFire software, supplied
by the manufacturer. Susceptibility results based on geno-
typic testing were compared using a phenotypic drug
susceptibility test.
Microscopic observation drug susceptibility assay
The MODS assay is a well-described microbiological
technique that has shown to be reliable, cheap, and
easy to implement in low-volume, low-resource settings
for drug susceptibility testing. The performance of the
MODS assay in identification of MDR-TB is excellent,
with a sensitivity of 97.8% and a specificity of 99.6%,
compared with standard drug susceptibility testingmethods [20]. The rapidity, simplicity, and low cost of
the MODS assay made it a promising candidate for use
as a methodology for second-line drug resistance testing
and XDR-TB detection. Although the MODS assay has
been validated for detection of resistance to first-line
drugs, a reliable methodology for detection of resistance
to ofloxacin, amikacin, kanamycin, and capreomycin has
not yet been established. The development of the MODS
assay for the detection of second-line drug resistance
has recently been described [21].
The MODS assay is a microscope-based assay that
exploits the fact that M. tuberculosis grows more rapidly
in liquid broth than solid medium and forms specific
‘cord’ formations that can be seen through the micro-
scope long before colonies on solid media are visible to
the naked eye. The MODS assay method uses a 24-well
culture plate format. Patient sputum samples were
digested and decontaminated according to a standard-
ized procedure and inoculated into culture broth with
and without the study drugs. The broth was then placed
in the culture plates. If the sample of M. tuberculosis
grew in broth alone, but not in drug-containing wells, if
was drug-sensitive. If M. tuberculosis also grew in drug-
containing wells, DR-TB was present. An advantage of
the MODS assay is its flexibility to test multiple drugs at
different concentrations at once. When used directly to
detect M. tuberculosis in sputum, results are available in
as early as seven days instead of two to three weeks
following positive culture [20].Sample size and power analysis
The primary outcome measure for Aim 1 was the time
to obtaining a drug susceptibility test result from the
new tests, in comparison with the approximate 21 days
that it typically takes to obtain this information using
the standard methodology of MGIT culture and indirect
drug susceptibility testing. Based on preliminary data of
the novel diagnostic tests and the scientific method-
ology, study investigators were confident that the time
to result would be shortened dramatically. Prior to study
launch, power analyses were conducted for each study
aim and the ideal sample size was determined using
PASS software (Number Cruncher Statistical Systems,
Kaysville, UT, USA, version 2005). This software was
used to calculate the power to conduct a two-sided
paired t test, assuming a significance level of 0.05, a null-
hypothesis difference of 0 day, an expected difference of
14 or 7 days, and an estimated standard deviation of
14 days. In a study with 100 patients with XDR-TB, we
would have 100% or 99.9% power to find a significant
reduction of 14 or 7 days, respectively. With as few as 10
patients having XDR-TB in a site, we would have 80.3%
power to find a significant reduction of 14 days. This
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smallest and most restrictive sample size.
The goal of Aim 2 was to examine the agreement of
the new tests with MGIT drug susceptibility tests for
detecting the resistance of samples to first- and second-
line medications. Here, the size of the confidence intervals
around the sensitivity and specificity for each diagnostic
test was a function of sample size and prevalence of resist-
ance. The prevalence of resistance varied quite widely
across the seven drugs examined, as well as across the
algorithms for diagnosing MDR-TB and XDR-TB. To be
conservative and align with the stated goals of the study,
we used an estimated prevalence for XDR-TB, since its
prevalence is much lower than MDR-TB. We estimated
that the prevalence of XDR-TB would be 5% to 10% for
the study. Based on preliminary study results, we esti-
mated that the new tests would achieve a sensitivity of
0.90 to 0.95 and a specificity of 0.95 to 0.98. There is no
standard on the ideal size of a confidence interval, simply
smaller is better, but huge sample sizes may be required
to accomplish this when detecting less prevalent cases.
In addition, as prevalence decreases, it is easier to be
confident about high specificity while harder to keep sensi-
tivity high. Therefore, we estimated the sample sizes
required to achieve confidence intervals of about 0.100 for
sensitivity and 0.020 for specificity. It was determined that
a sample size of 1,225 subjects would provide a confidence
interval of 0.077 for a sensitivity of 0.95 and 0.017 for a
specificity of 0.98 at an XDR-TB prevalence of 10%. If the
prevalence of XDR-TB were as low as 5%, 1,225 subjects
would provide a confidence interval of 0.105 for a sensitiv-
ity of 0.95 and 0.016 for a specificity of 0.98. This same
sample size produces much tighter confidence intervals for
MDR-TB, where prevalence is higher. At 35% MDR-TB
prevalence, we obtain confidence intervals of 0.041 for a
sensitivity of 0.95 and 0.018 for a specificity of 0.98.
Aim 3 (to identify the genetic basis of discordant results
from Aim 2) was a developmental aim, and did not test
specific hypotheses. Aim 4 (to characterize XDR-TB strains
globally) was a descriptive analysis. It also did not test spe-
cific hypotheses. We expected a sample size of 1,225 to
provide more than enough data to explore discordant re-
sults with genetic sequencing and characterize global
strains using genotypic, phenotypic, epidemiological, and
geographical variables.
The study did not randomize patients in the clinical
data collection phase because it would have severely
limited the statistical power of the confidence intervals
for sensitivity and specificity calculations, and compro-
mised our ability to complete the study. Instead, we
chose to conduct all four resistance tests on every sam-
ple, allowing approximately 900 to 1,000 comparisons
for each test. If patients were randomized to receive




The study operated under a centralized study manage-
ment group of administrators and laboratory technicians
at the University of California, San Diego, under the
supervision of the principal investigator, Dr. Antonino
Catanzaro. Several committees existed within the study
framework so that co-investigators could provide key
advice as the study progressed. Working groups who
met regularly were an operations and data committee, a
microbiology core unit, a leadership committee, and a
publications committee; the first two groups addressed
specific operational and technical laboratory issues to
move the study forward, respectively, and freed the
leadership committee to discuss larger-scale topics
related to study progress. The publications committee,
which comprised of two co-investigators and one external
expert in TB research, steered efforts for the publication
of key findings. Additionally, each international study site
had a local team, which included principal investigators, a
study coordinator, clinicians, and laboratory technicians.
Site teams were responsible for recruitment, data collec-
tion and transmission, sample processing, and participant
follow-up.
Website
To share critical information and study documents, a
GCDD website was established and utilized regularly
throughout the study [22]. This website housed protocols,
standard operating procedures, case report forms, meeting
agendas and minutes, presentations, publications, contact
lists, and reports for the central study management or sites
to view, and in some cases, download to provide responses.
Users at the sites could upload requested source docu-
ments via the website directly to the data coordinating
center and were able to access electronic data capture
ystems for data entry. Moreover, the website allowed for
access levels to be specified so that confidential informa-
tion was protected from unauthorized users. The GCDD
website was managed by the data coordinating center, and
will continue to be maintained after the study funding
period, allowing for public requests to access to study data.
Site visits
Visits to enrollment sites were required by a representative
of Family Health International prior to study initiation.
The objectives of these visits were to conduct a general
assessment of the site and to gather information on its
structure and organization, as it pertained to compliance
with good clinical practices and other requirements of
the National Institutes of Health. Advice was given on
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quirements. The principal investigator and co-investigators
also visited the sites to verify compliance with standard op-
erating procedures and respond to questions or difficulties
encountered in executing the study protocol. These pre-
paratory visits occurred before or during the validation
phase. During the clinical observation phase, co-
investigators visited India and Moldova to monitor study
progress.
Data management
The University of California, San Diego, Health Services
Research Center, a multidisciplinary team of researchers,
database managers, and programmers, acted as the data
coordinating center, collecting and managing study data.
The study also employed a quality assurance manager
who worked in collaboration with the data coordinating
center to ensure high-quality data throughout the study.
All data were stored and managed in a secure SQL data-
base using SQL Server Management Studio, version
2012.
A top priority of this study was to protect subject con-
fidentiality. All data entry systems were password pro-
tected and only the clinician enrolling subjects had
access to personally identifying information, such as
name, date of birth, or contact information. These were
used only for follow-up purposes. Clinicians were
instructed how to password protect the document con-
taining personally identifying information so that the
data managers and programmers were blinded to this in-
formation when accessing the laptop. Study personnel
were instructed never to document the participants’
names and study identification numbers in the same lo-
cation on any study document.
Data capture systems
Data were gathered by two independent electronic data
capture systems: clinical case report forms were entered
directly into a password-protected study laptop as clini-
cians interviewed subjects or gathered medical record
information via software designed specifically for this
study. This application allowed the user to collect data
off-line (a function critical for enrollment in more rural
locations where internet connection was not reliable)
and then allowed upload of data to the database when a
connection became available. This software also enabled
users to save their progress until a later time if needed
and assigned the unique identifier that the participant
and associated samples carried throughout the study.
The second was a web form system designed by the
Health Services Research Center for the collection of la-
boratory case report forms. Study data were gathered
from original laboratory result sheets upon test comple-
tion and documented on study case report forms. Thelaboratory technicians then entered this information into
web forms and uploaded the data directly to the data-
base, as all central laboratories had reliable internet con-
nections. The system was comprised of 13 individual
web forms. Each sent an automated confirmation email
to the site coordinator and the data manager whenever
forms were uploaded, as verification of database receipt.
Remote access
Owing to the physical distance between the data coord-
inating center and the study sites, provisions were put
into place to troubleshoot technical difficulties remotely.
The study utilized the web tool Log Me In [23]. This
enabled database managers and programmers to access
study laptops when they were connected to the internet,
allowing identified problems to be resolved promptly, so
that enrollment could progress normally.
Data quality assurance and control measures
We utilized several front-end quality assurance measures
in the electronic data entry form fields to prevent incorrect
data from being included in the database. For instance,
electronic forms would not accept a duplicate case and
date fields would accept only a response in date format
(and only current or past dates, local time). Although these
types of front-end quality assurance measures existed on
almost every field in each form, some data points still re-
quired internal validity checks to verify that information
between case report forms was consistent. For these, back-
end quality control measures were employed, such as date
checks of when laboratory procedures were performed; if a
date of test completion for a drug susceptibility test was
entered as earlier than the sample processing date, the site
would be queried, as this was an illogical process of events.
Similarly, if a medication stop date was earlier than the
start date, the site would be asked to verify and correct the
information.
As a final level of quality control, the microbiology core
unit reviewed all laboratory data from 100% of enrolled
subjects to ensure that results were logical in the context
of the patient. This routine also helped to identify trends
that would potentially affect study outcomes, such as the
need to repeat drug susceptibility tests or the detection of
a high rate of smear negative samples. The sites were gen-
erally able to execute successfully the protocol. A review
by microbiologists vetted the scientific quality of the com-
plex data and allowed data managers to focus on more
routine data queries, such as ranges and basic internal
validity.
Data correction procedures
Data correction was carefully considered as part of the
routine data management of the study. If queries by the
data manager or quality assurance manager resulted in
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asked to respond specifically within the same report or
to fill out an electronic data correction form housed on
the GCDD website. If a site identified an error in its
own data, the same mechanism could be used to report
it. As data corrections were sent to the data coordinating
center, the data manager reviewed the changes, and an
ongoing SQL database query was updated. This query
updated the values of a specific case in accordance with
the documented error in a new copy of the data table, so
that raw data would be preserved. Only these updated
tables were used for analysis. While every effort was
made to prevent erroneous data before receipt in the
database, this could not always prevent inaccuracies.
Establishing a procedure early in the study kept the
requests manageable.
Data monitoring and reporting
The high volume of information collected made it import-
ant to monitor study data in real time. We developed
progress reports to ensure that sites regularly transmitted
data and to keep collaborators informed of study progress.
Many of these reports were run weekly, while others were
run monthly. Weekly reports included counts of enroll-
ment, defined by the receipt of the first expected post-
screening measure (the enrollment interview case report
form); counts of laboratory processing forms by subject;
and date of last upload for each measure. Further, the
length of time between expected upload and actual upload
for each case report form were monitored. It was import-
ant to assess clinics and laboratories separately as the
processes for each type of data collection were expected
to take differing lengths of time. Further, timeliness of re-
sponses was affected in part by number of staff members
available to assist at each site. A standard protocol was
utilized for inquiring about overdue data and reports: first,
the data manager reported to the clinical manager follo-
wing two unresponsive requests to the staff member
responsible. If still unresponsive, the clinical manager
escalated to the principal investigator, who contacted the
site principal investigator directly. It was rare for any
request to progress this far, but allowing for this possibility
ensured that data monitoring issues were handled consist-
ently and in a timely fashion.
In addition to monitoring the time for receipt of case re-
port forms, we developed detailed reports called reconcili-
ation reports. These site-specific reports included a list of
all study IDs and which forms were received, overdue, or
not yet due. For outstanding forms, it was requested that
sites respond monthly with the status of each. Problems
observed in timely data collection were followed up by the
data manager, quality assurance manager, and clinical
manager. Generally, these reports served as a reminder of
what follow-up forms were upcoming or overdue, but attimes they also informed managers of more serious in-
ternal issues, such as a lack of study supplies to complete
a test, and therefore, a case report form.
As data were needed for interim analyses, such as
sensitivity and specificity, or the time to result of each
rapid test, the database was queried and output was
provided in a Microsoft Excel spreadsheet and either
emailed to the requestor or posted on the GCDD website.
Accompanying documentation was supplied on the website
throughout the study. A final data table query was written
to compute study outcomes that considered multiple fields.
This assisted with generating datasets for analysis much
more quickly than on an as-needed basis.
Study subjects’ drug susceptibility test results were
made available to the treating physicians at each site.
Clinicians were carefully informed of the research nature
of the test results and that treatment decisions should
not be based solely on the results of study tests. All TB
treatment that the subjects received was determined and
administered by the local TB clinicians. Treatment or
treatment recommendations were not provided through
the study. It was emphasized that the results obtained
were for research purposes only.
Results and discussion
Detection time to XDR-TB diagnosis remains a challenge.
This study design was intended to advance the develop-
ment and validation of molecular-based technologies (line
probe assay and pyrosequencing) and one microbiological
method (MODS assay), which have proven success for the
rapid detection of MDR-TB in low-resource settings.
Geographic and TB strain differences were expected to
affect the genetic mutations associated with drug resistance
that were observed, making it important to study the mo-
lecular basis for drug resistance and evaluate the perform-
ance of rapid diagnostic tests for XDR-TB across different
clinical settings. This paper discussed the methodologies
used to produce data pertinent to these aims and issues
encountered were described.
All sites completed the validation procedures success-
fully. There are potentially useful data and samples avail-
able from that phase of the study that may be described
in future publications. The validation phase of the study
was critical to testing and modifying the methodologies
described. One such adjustment was for the required
volume of sputum to maintain eligibility: the validation
phase began with a minimum 5 ml of sputum on the first
visit from each participant; however, it was determined
that to complete all laboratory processes, it would be
necessary to raise this minimum to 7.5 ml of pooled spu-
tum. Although the minimum volume increased, applying
it to the pooled sputum allowed the morning specimen to
be included, allowing a greater chance for screened partic-
ipants to meet this minimum. This did somewhat affect
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due to a lack of 5 ml sputum on the first visit and 7.5
pooled were 0.8% and 3.1%, respectively. Despite the
increased withdrawal rate, all subjects who were retained
in the study had adequate samples to meet testing require-
ments, so that resources could be directed appropriately.
In a study of this size, working efficiently and evaluating
the outcome of all decisions was incredibly important.
In addition, the ability to monitor enrollment and data
entry targets in real time was an important feature of the
study design. This allowed any problems with achieving
enrollment goals to be addressed quickly and kept
researchers well informed of sample size as the study pro-
gressed. As data were received in the database, multiple
levels of data quality checks were put into use throughout
the study. These validations and queries at times revealed
both systematic and random errors. While these inaccur-
acies pointed to improvements that could be made in
training data collection staff or to data capture systems, it
was the job of the operations and data committee to deter-
mine which situations required retraining and which
would necessitate improvement of systems or quality con-
trol measures. Although careful planning went into each
of the case report forms, it is recommended that case
report forms and electronic data capture field validations
be thoroughly examined by clinical and laboratory
personnel prior to enrollment so that internally valid data
can be captured with minimum burden on data entry staff.
Further, changes to data points being collected might
occur but should be tested thoroughly, so as to avoid
introduction of new errors within the database. All data
should be traceable to a source document, so that infor-
mation can be followed up. The ability to monitor data
quality in real time was significant to identification and
resolution of problems that could have severely affected
the quality of the final data.
Direct communication with enrollment sites and labora-
tories were also critical to the study’s success. Monthly
site-specific teleconferences were implemented with the
central leadership committee and all staff at each of the
study sites, so that issues specific to the study site could
be the primary focus of conversation. These calls allowed
the opportunity to discuss details of requests made in
either direction and specific data issues needing reso-
lution, and to provide assistance with troubleshooting
equipment problems. This teleconference format was
highly productive for this study, as it kept all parties
accountable for necessary actions and was more efficient
than email communications, which had inherent delays
due to time zone differences. It also allowed input from all
collaborators, giving confidence that all departments
involved were considered when decisions were needed.
Further, annual webinars included presentations of data
to date, site collaboration, and feedback to the centralleadership. These regular communications played a vital
role in detecting issues and solutions that were not picked
up through routine queries and gave sites the opportunity
to share experiences with one another.
The diversity of study locations where recruitment
took place was crucial for comparative analyses but was
not without challenges. Although many circumstances
were planned for, such as implementing provisions for
physical distance between the coordinating center and
study sites, challenges arose that required consideration
and decision-making by the central leadership. For
instance, India was the only study site where patients
routinely carried their own medical records, as opposed to
them being stored at the clinic. This affected follow-up, as
subjects were initially only expected to return at day 2 and
week 52 for follow-up visits. While this remained the case
in Moldova and South Africa, subjects from the India site
were asked to return to the clinic 30 days after enrollment
to supply chart review information, causing difficulty in
obtaining this follow-up measure as quickly as the other
two sites, where medical records were stored at the clinic.
To improve the success rates of follow-up, it was deter-
mined that this site could collect the 30-day data by
telephone, by having the subjects read the information
from the record. Additionally, the Moldova and South
Africa study sites did not have the same patient vol-
umes as the India site, so recruitment was at a slower
pace. These needed to be accounted for in recruitment
targets. Each site also observed unique holidays and
clinic closures, which affected the pace of recruitment.
It is recommended that access to medical records,
patient volume, and local schedules be carefully con-
sidered prior to study launch so that they can be
accommodated.
Conclusions
In summary, we have documented the methodology
used in a global multi-site DR-TB study for the
advancement of diagnostic tools. By conducting a large
prospective study, which captured epidemiological,
clinical, and biological data, we have produced a high-
quality and unique dataset, which will be beneficial for
analyzing study aims as well as answering future
DR-TB research questions. Analyses and main findings
of the GCDD study are forthcoming. We will also con-
tinue to analyze the repository of isolates and DNA
gathered from this study, as they are an invaluable
resource to evaluate new diagnostic devices as they
become available. Reduction in detection time for
XDR-TB would be a major public health success, as it
would allow for improved treatment and more succe-
ssful patient outcomes. Executing successful trials is
critical in assessment of these reductions in highly vari-
able populations.
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